JP2025513462A5 - - Google Patents
Info
- Publication number
- JP2025513462A5 JP2025513462A5 JP2024562090A JP2024562090A JP2025513462A5 JP 2025513462 A5 JP2025513462 A5 JP 2025513462A5 JP 2024562090 A JP2024562090 A JP 2024562090A JP 2024562090 A JP2024562090 A JP 2024562090A JP 2025513462 A5 JP2025513462 A5 JP 2025513462A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263332450P | 2022-04-19 | 2022-04-19 | |
| US63/332,450 | 2022-04-19 | ||
| PCT/CA2023/050523 WO2023201423A1 (en) | 2022-04-19 | 2023-04-18 | Indoline derivatives as serotonergic agents useful for the treatment of disorders related thereto |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2025513462A JP2025513462A (ja) | 2025-04-24 |
| JP2025513462A5 true JP2025513462A5 (https=) | 2026-04-23 |
| JPWO2023201423A5 JPWO2023201423A5 (https=) | 2026-04-23 |
Family
ID=88418733
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024562090A Pending JP2025513462A (ja) | 2022-04-19 | 2023-04-18 | セロトニン作動薬としてのインドリン誘導体に関連する障害の治療に有用なセロトニン作動薬としてのインドリン誘導体 |
| JP2024562088A Pending JP2025513461A (ja) | 2022-04-19 | 2023-04-18 | セロトニン作動薬としてのインドリン誘導体に関連する障害の治療に有用なセロトニン作動薬としてのインドリン誘導体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024562088A Pending JP2025513461A (ja) | 2022-04-19 | 2023-04-18 | セロトニン作動薬としてのインドリン誘導体に関連する障害の治療に有用なセロトニン作動薬としてのインドリン誘導体 |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US20250353827A1 (https=) |
| EP (2) | EP4511369A4 (https=) |
| JP (2) | JP2025513462A (https=) |
| KR (2) | KR20250034020A (https=) |
| CN (2) | CN119546591A (https=) |
| AU (2) | AU2023258059A1 (https=) |
| CA (2) | CA3248179A1 (https=) |
| IL (2) | IL316401A (https=) |
| MX (2) | MX2024012865A (https=) |
| WO (2) | WO2023201421A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL318929A (en) * | 2022-08-29 | 2025-04-01 | Mindset Pharma Inc | Indoline derivatives as serotonergic agents useful for the treatment of related disorders |
| WO2025104491A1 (en) * | 2023-11-14 | 2025-05-22 | Mindset Pharma Inc. | Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto |
| WO2025123137A1 (en) * | 2023-12-15 | 2025-06-19 | 10763942 Canada Inc. (Dba. Purminds Neuropharma) | Heterocyclic compounds and methods of preparation thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2737725B1 (fr) * | 1995-08-08 | 1997-10-31 | Valentonine | Nouveaux derives acyles de la melatonine et d'analogues melatoninergiques, leur procede de preparation et leur utilisation en tant que medicament |
| EP0944595B1 (en) * | 1996-11-26 | 2003-10-01 | NPS Allelix Corp. | 5-cyclo indole compounds as 5-ht1d receptor ligands |
| CZ295937B6 (cs) * | 1997-07-25 | 2005-12-14 | H. Lundbeck A/S | Indolové nebo 2,3-dihydroindolové deriváty |
| GB9819033D0 (en) * | 1998-09-01 | 1998-10-28 | Cerebrus Ltd | Chemical compounds VI |
| US6608079B1 (en) * | 1998-12-11 | 2003-08-19 | Eli Lilly And Company | Indole derivatives and their use as 5-HT1F agonists |
| AU2003236207A1 (en) * | 2002-05-31 | 2003-12-19 | H. Lundbeck A/S | The hydrochloride of (s)-(+)-3-(1-(2-(1-acetyl-2,3-dihydro-1h-indol-3-yl)ethyl)-1,2,3,6-tetrahydropyridin-4-yl)-6-chloro-1h-indole |
| WO2005084664A1 (ja) * | 2004-03-08 | 2005-09-15 | Kanazawa University Technology Licensing Organization Ltd. | インドール誘導体及びその用途 |
| CL2007002166A1 (es) * | 2006-07-24 | 2008-01-25 | Tetralogic Pharm Corp | Compuestos derivados de heterociclos de nitrogeno, antagonistas de los inhibidores de las proteinas de la apoptosis; sus composiciones farmaceuticas; y uso de dichos compuestos para el tratamiento del cancer. |
| MX2022009528A (es) * | 2020-02-04 | 2022-11-14 | Mindset Pharma Inc | Derivados de 3-pirrolidina-indol como agentes psicodélicos serotoninérgicos para el tratamiento de trastornos del snc. |
-
2023
- 2023-04-18 KR KR1020247038407A patent/KR20250034020A/ko active Pending
- 2023-04-18 WO PCT/CA2023/050521 patent/WO2023201421A1/en not_active Ceased
- 2023-04-18 EP EP23790806.6A patent/EP4511369A4/en active Pending
- 2023-04-18 US US18/857,230 patent/US20250353827A1/en active Pending
- 2023-04-18 JP JP2024562090A patent/JP2025513462A/ja active Pending
- 2023-04-18 JP JP2024562088A patent/JP2025513461A/ja active Pending
- 2023-04-18 CA CA3248179A patent/CA3248179A1/en active Pending
- 2023-04-18 AU AU2023258059A patent/AU2023258059A1/en active Pending
- 2023-04-18 IL IL316401A patent/IL316401A/en unknown
- 2023-04-18 CA CA3248170A patent/CA3248170A1/en active Pending
- 2023-04-18 EP EP23790804.1A patent/EP4511360A4/en active Pending
- 2023-04-18 KR KR1020247038406A patent/KR20250036719A/ko active Pending
- 2023-04-18 AU AU2023255414A patent/AU2023255414A1/en active Pending
- 2023-04-18 IL IL316416A patent/IL316416A/en unknown
- 2023-04-18 US US18/857,234 patent/US20260083703A1/en active Pending
- 2023-04-18 WO PCT/CA2023/050523 patent/WO2023201423A1/en not_active Ceased
- 2023-04-18 CN CN202380048473.6A patent/CN119546591A/zh active Pending
- 2023-04-18 CN CN202380048482.5A patent/CN119522212A/zh active Pending
-
2024
- 2024-10-17 MX MX2024012865A patent/MX2024012865A/es unknown
- 2024-10-17 MX MX2024012864A patent/MX2024012864A/es unknown